Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 23
- Jan 25, 2025
Preliminary Results From a Randomized, Open-Label, Phase 2 Study of BotensilimabWith or Without Balstilimab in Refractory Microsatellite Stable Metastatic Colorectal Cancer With No Liver Metastases
Fakih, et al.
Filter by
INCAGN2390 (TIM-3 Antagonist)
American Association for Cancer Research (AACR)
Apr 14
- Apr 18, 2018
INCAGN02390, a Novel Antagonist Antibody That Targets the Co-Inhibitory Receptor TIM-3.
Waight, et al.
INCAGN2385 (LAG-3 Antagonist)
American Association for Cancer Research (AACR)
Apr 14
- Apr 18, 2018
INCAGN02385 is an Antagonist Antibody Targeting the Co-Inhibitory Receptor LAG-3 for the Treatment of Human Malignancies.
Savitsky, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Frontiers in Immunology
Oct 22, 2019
TCR Fingerprinting and Off-Target Peptide Identification.
Karapetyan, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 6
- Nov 10, 2019
TCR Fingerprinting and Off-Target Peptide Identification.
Karapetyan, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
AgenT-797, a novel allogenic and “off-the shelf” iNKT cell therapy promotes effective tumor killing.
Burcu, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 10
- Nov 14, 2021
Identification and characterization of an allogeneic iNKT-CAR targeting BCMA.
Michelet, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 10
- Nov 14, 2021
AgenT-797, a native allogeneic “off-the-shelf” iNKT cell therapy product shows anti-tumor activity in preclinical xenograft models.
Yigit, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 10
- Nov 14, 2021
Persistence and tissue distribution of Agent-797 – a native allogeneic iNKT cell-therapy drug product.
Purbhoo, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Cancer Cell
Jun 11, 2018
Selective FcgR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.
Waight, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society of Clinical Oncology (ASCO)
May 29
- May 31, 2020
AGEN1181, a Clinical Stage Fc-Engineered anti-CTLA-4 Antibody with Improved Therapeutic Potential for the Treatment of Patients with Advanced Malignancies.
O’Day, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Jun 22
- Jun 24, 2020
Expanding the Therapeutic Potential of anti-PD-1 and anti-CTLA-4 Therapy with Innovative Fc Engineering and Rationale Combinations for the Treatment of Solid Tumors.
Tanne, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy.
O’Day, et al.